Maryam Asgari
Concepts (506)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 97 | 2024 | 760 | 22.780 |
Why?
| Carcinoma, Squamous Cell | 54 | 2024 | 577 | 14.540 |
Why?
| Carcinoma, Basal Cell | 22 | 2024 | 68 | 8.790 |
Why?
| Melanoma | 24 | 2023 | 649 | 4.720 |
Why?
| Keratosis, Actinic | 9 | 2024 | 11 | 4.170 |
Why?
| Dermatology | 12 | 2020 | 86 | 4.070 |
Why?
| Psoriasis | 8 | 2023 | 76 | 3.040 |
Why?
| Dermatologic Agents | 8 | 2019 | 57 | 2.880 |
Why?
| Genetic Loci | 6 | 2020 | 280 | 2.350 |
Why?
| Vitamin D | 10 | 2021 | 341 | 2.350 |
Why?
| Neoplasms, Multiple Primary | 4 | 2019 | 52 | 2.180 |
Why?
| California | 22 | 2018 | 368 | 2.150 |
Why?
| Genetic Predisposition to Disease | 13 | 2022 | 2201 | 2.140 |
Why?
| Keratinocytes | 12 | 2020 | 218 | 2.060 |
Why?
| Dermatitis, Atopic | 6 | 2023 | 337 | 2.060 |
Why?
| Risk Assessment | 20 | 2023 | 2992 | 1.900 |
Why?
| Mohs Surgery | 5 | 2021 | 24 | 1.730 |
Why?
| Transplant Recipients | 6 | 2021 | 143 | 1.680 |
Why?
| Incidence | 23 | 2024 | 2336 | 1.590 |
Why?
| Humans | 155 | 2024 | 115859 | 1.560 |
Why?
| Middle Aged | 68 | 2023 | 27078 | 1.560 |
Why?
| Aged | 62 | 2023 | 19292 | 1.560 |
Why?
| Risk Factors | 39 | 2024 | 8715 | 1.510 |
Why?
| Cohort Studies | 30 | 2023 | 4960 | 1.470 |
Why?
| Organ Transplantation | 7 | 2021 | 161 | 1.470 |
Why?
| Registries | 8 | 2018 | 1772 | 1.320 |
Why?
| Fluorouracil | 5 | 2023 | 151 | 1.320 |
Why?
| Male | 88 | 2023 | 56103 | 1.310 |
Why?
| Aged, 80 and over | 30 | 2020 | 6434 | 1.260 |
Why?
| Genome-Wide Association Study | 11 | 2024 | 1277 | 1.230 |
Why?
| Polymorphism, Single Nucleotide | 12 | 2024 | 2004 | 1.220 |
Why?
| Female | 86 | 2023 | 60070 | 1.210 |
Why?
| Biological Products | 3 | 2021 | 172 | 1.140 |
Why?
| Needs Assessment | 6 | 2018 | 320 | 1.130 |
Why?
| Immunosuppressive Agents | 6 | 2021 | 666 | 1.110 |
Why?
| Papillomaviridae | 4 | 2019 | 100 | 1.100 |
Why?
| Follow-Up Studies | 17 | 2020 | 4443 | 1.070 |
Why?
| Dietary Supplements | 5 | 2014 | 460 | 1.050 |
Why?
| Health Services Needs and Demand | 3 | 2012 | 249 | 1.040 |
Why?
| Adult | 49 | 2023 | 30814 | 1.000 |
Why?
| Skin Pigmentation | 3 | 2020 | 39 | 0.980 |
Why?
| Carcinoma, Merkel Cell | 5 | 2016 | 17 | 0.970 |
Why?
| Skin Diseases | 3 | 2023 | 124 | 0.950 |
Why?
| Precision Medicine | 3 | 2022 | 356 | 0.940 |
Why?
| Retrospective Studies | 30 | 2023 | 12615 | 0.940 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 301 | 0.910 |
Why?
| Delivery of Health Care | 4 | 2020 | 847 | 0.870 |
Why?
| Sex Factors | 6 | 2019 | 1741 | 0.870 |
Why?
| Sunlight | 4 | 2018 | 57 | 0.830 |
Why?
| Early Detection of Cancer | 3 | 2023 | 340 | 0.820 |
Why?
| Evidence-Based Medicine | 3 | 2019 | 685 | 0.780 |
Why?
| Carcinoma | 2 | 2020 | 200 | 0.770 |
Why?
| SEER Program | 3 | 2017 | 195 | 0.760 |
Why?
| Genetic Background | 1 | 2020 | 8 | 0.760 |
Why?
| Mendelian Randomization Analysis | 1 | 2021 | 45 | 0.750 |
Why?
| Hidradenitis Suppurativa | 1 | 2020 | 9 | 0.730 |
Why?
| Calcineurin Inhibitors | 1 | 2020 | 59 | 0.720 |
Why?
| Valproic Acid | 1 | 2020 | 43 | 0.710 |
Why?
| Antihypertensive Agents | 3 | 2018 | 432 | 0.690 |
Why?
| Point-of-Care Systems | 1 | 2021 | 150 | 0.680 |
Why?
| Drug Approval | 2 | 2019 | 78 | 0.680 |
Why?
| Orphan Drug Production | 1 | 2019 | 6 | 0.680 |
Why?
| Outpatient Clinics, Hospital | 1 | 2020 | 79 | 0.680 |
Why?
| Women, Working | 1 | 2019 | 9 | 0.670 |
Why?
| Proportional Hazards Models | 9 | 2017 | 1088 | 0.670 |
Why?
| HLA-DRB1 Chains | 1 | 2019 | 99 | 0.670 |
Why?
| Myotonic Dystrophy | 1 | 2019 | 5 | 0.660 |
Why?
| Salaries and Fringe Benefits | 1 | 2019 | 53 | 0.650 |
Why?
| Databases, Factual | 8 | 2019 | 1137 | 0.650 |
Why?
| Patient Care | 1 | 2019 | 103 | 0.650 |
Why?
| Epidemiologic Methods | 1 | 2019 | 73 | 0.650 |
Why?
| Managed Care Programs | 3 | 2017 | 135 | 0.650 |
Why?
| Physicians, Women | 1 | 2019 | 55 | 0.630 |
Why?
| Rare Diseases | 1 | 2019 | 90 | 0.630 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2020 | 198 | 0.630 |
Why?
| Young Adult | 19 | 2023 | 10508 | 0.630 |
Why?
| Photosensitizing Agents | 1 | 2018 | 26 | 0.630 |
Why?
| Electronic Health Records | 3 | 2021 | 805 | 0.630 |
Why?
| Models, Statistical | 2 | 2019 | 612 | 0.620 |
Why?
| Vitamin D Deficiency | 3 | 2021 | 159 | 0.620 |
Why?
| Genes, MHC Class II | 1 | 2018 | 69 | 0.620 |
Why?
| Aminoquinolines | 1 | 2017 | 20 | 0.610 |
Why?
| Vitamins | 5 | 2021 | 151 | 0.610 |
Why?
| Sex Distribution | 6 | 2017 | 337 | 0.600 |
Why?
| Lentigo | 1 | 2017 | 5 | 0.600 |
Why?
| Lithium | 1 | 2017 | 36 | 0.580 |
Why?
| DNA Virus Infections | 1 | 2017 | 4 | 0.580 |
Why?
| Haplotypes | 2 | 2018 | 475 | 0.570 |
Why?
| Lymph Node Excision | 2 | 2015 | 141 | 0.560 |
Why?
| Mass Screening | 2 | 2023 | 1024 | 0.560 |
Why?
| Opioid-Related Disorders | 2 | 2021 | 422 | 0.550 |
Why?
| Patient Satisfaction | 2 | 2011 | 585 | 0.550 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 533 | 0.550 |
Why?
| Interferon Regulatory Factors | 1 | 2016 | 30 | 0.550 |
Why?
| Prognosis | 13 | 2018 | 3344 | 0.550 |
Why?
| Genomics | 2 | 2019 | 653 | 0.540 |
Why?
| Glucocorticoids | 1 | 2020 | 551 | 0.530 |
Why?
| HLA Antigens | 1 | 2017 | 224 | 0.510 |
Why?
| Bacterial Infections | 1 | 2017 | 222 | 0.510 |
Why?
| Quality Improvement | 3 | 2020 | 958 | 0.510 |
Why?
| Membrane Transport Proteins | 1 | 2016 | 137 | 0.510 |
Why?
| Research Design | 3 | 2019 | 949 | 0.510 |
Why?
| Community Health Services | 1 | 2017 | 212 | 0.510 |
Why?
| Biomedical Research | 2 | 2019 | 589 | 0.500 |
Why?
| Antigens, Neoplasm | 1 | 2016 | 224 | 0.490 |
Why?
| United States | 18 | 2023 | 12319 | 0.490 |
Why?
| Quality of Health Care | 1 | 2019 | 577 | 0.490 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 242 | 0.490 |
Why?
| Neoplasms, Unknown Primary | 1 | 2014 | 12 | 0.480 |
Why?
| Neoplasms, Second Primary | 1 | 2015 | 91 | 0.470 |
Why?
| Models, Biological | 2 | 2019 | 1647 | 0.470 |
Why?
| Sirolimus | 1 | 2015 | 192 | 0.470 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 666 | 0.460 |
Why?
| Adenocarcinoma, Papillary | 1 | 2013 | 9 | 0.460 |
Why?
| Analgesics, Opioid | 2 | 2021 | 783 | 0.460 |
Why?
| Herpes Zoster | 1 | 2018 | 333 | 0.460 |
Why?
| Confidence Intervals | 6 | 2017 | 309 | 0.450 |
Why?
| Population Surveillance | 1 | 2016 | 395 | 0.450 |
Why?
| Odds Ratio | 7 | 2017 | 968 | 0.450 |
Why?
| Kidney Transplantation | 1 | 2019 | 559 | 0.450 |
Why?
| Adolescent | 19 | 2023 | 17935 | 0.440 |
Why?
| Arthritis, Psoriatic | 1 | 2013 | 16 | 0.440 |
Why?
| Carcinoma, Large Cell | 1 | 2013 | 14 | 0.430 |
Why?
| Prevalence | 9 | 2024 | 2270 | 0.430 |
Why?
| Risk | 4 | 2019 | 829 | 0.430 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2013 | 64 | 0.420 |
Why?
| Mitochondria | 1 | 2018 | 749 | 0.420 |
Why?
| Logistic Models | 7 | 2018 | 1863 | 0.410 |
Why?
| Neuroectodermal Tumor, Melanotic | 1 | 2012 | 1 | 0.410 |
Why?
| Age Distribution | 4 | 2017 | 341 | 0.410 |
Why?
| Carotenoids | 1 | 2012 | 35 | 0.410 |
Why?
| Vitamin A | 1 | 2012 | 52 | 0.400 |
Why?
| Epidermis | 1 | 2012 | 150 | 0.400 |
Why?
| Skin Aging | 1 | 2011 | 19 | 0.400 |
Why?
| Lymph Nodes | 1 | 2014 | 423 | 0.390 |
Why?
| Hypertension | 3 | 2018 | 1065 | 0.390 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 862 | 0.390 |
Why?
| Surgery, Plastic | 1 | 2011 | 25 | 0.390 |
Why?
| Case-Control Studies | 7 | 2023 | 3054 | 0.380 |
Why?
| Tea | 1 | 2011 | 10 | 0.380 |
Why?
| HIV Infections | 2 | 2017 | 2471 | 0.380 |
Why?
| Skin | 5 | 2022 | 668 | 0.360 |
Why?
| Massachusetts | 3 | 2021 | 137 | 0.360 |
Why?
| Neoplasm Staging | 7 | 2023 | 1177 | 0.360 |
Why?
| Age Factors | 6 | 2018 | 2911 | 0.350 |
Why?
| Contraceptives, Oral | 1 | 2010 | 25 | 0.350 |
Why?
| United States Food and Drug Administration | 3 | 2019 | 173 | 0.340 |
Why?
| Global Health | 2 | 2024 | 290 | 0.320 |
Why?
| Patient Participation | 1 | 2011 | 362 | 0.310 |
Why?
| Sunbathing | 2 | 2018 | 13 | 0.310 |
Why?
| Disease Susceptibility | 2 | 2020 | 321 | 0.300 |
Why?
| Enhancer Elements, Genetic | 2 | 2020 | 153 | 0.300 |
Why?
| Genetic Association Studies | 2 | 2019 | 352 | 0.300 |
Why?
| Head and Neck Neoplasms | 2 | 2014 | 425 | 0.290 |
Why?
| Practice Patterns, Physicians' | 4 | 2017 | 1182 | 0.290 |
Why?
| Anticholesteremic Agents | 1 | 2009 | 129 | 0.290 |
Why?
| Comorbidity | 4 | 2018 | 1476 | 0.290 |
Why?
| Administration, Topical | 2 | 2017 | 137 | 0.290 |
Why?
| Education, Medical, Continuing | 3 | 2019 | 119 | 0.290 |
Why?
| Head Movements | 1 | 2007 | 18 | 0.290 |
Why?
| DNA, Viral | 2 | 2012 | 351 | 0.280 |
Why?
| Hemangiosarcoma | 1 | 2007 | 19 | 0.280 |
Why?
| Survival Rate | 5 | 2017 | 1649 | 0.280 |
Why?
| Reference Values | 3 | 2017 | 745 | 0.280 |
Why?
| Papillomavirus Infections | 4 | 2019 | 258 | 0.280 |
Why?
| Morbidity | 3 | 2016 | 278 | 0.280 |
Why?
| Computational Biology | 2 | 2020 | 540 | 0.270 |
Why?
| Prospective Studies | 8 | 2018 | 6276 | 0.270 |
Why?
| Drug Costs | 2 | 2017 | 91 | 0.270 |
Why?
| Polymorphism, Genetic | 3 | 2019 | 633 | 0.270 |
Why?
| Skin Diseases, Vesiculobullous | 1 | 2006 | 17 | 0.270 |
Why?
| Treatment Outcome | 9 | 2023 | 9163 | 0.260 |
Why?
| Delivery of Health Care, Integrated | 2 | 2022 | 231 | 0.260 |
Why?
| Neoplasm Invasiveness | 3 | 2017 | 445 | 0.260 |
Why?
| Calcifediol | 2 | 2018 | 29 | 0.260 |
Why?
| Antioxidants | 1 | 2009 | 534 | 0.260 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 373 | 0.250 |
Why?
| Surveys and Questionnaires | 8 | 2018 | 4673 | 0.250 |
Why?
| Nose | 1 | 2005 | 56 | 0.250 |
Why?
| CD4 Lymphocyte Count | 2 | 2017 | 257 | 0.250 |
Why?
| Ultraviolet Rays | 4 | 2019 | 372 | 0.240 |
Why?
| Infant, Premature, Diseases | 1 | 2006 | 91 | 0.240 |
Why?
| Photochemotherapy | 2 | 2021 | 29 | 0.240 |
Why?
| Fibrosarcoma | 1 | 2004 | 20 | 0.230 |
Why?
| Eosinophilia | 1 | 2006 | 187 | 0.230 |
Why?
| Surgical Flaps | 1 | 2005 | 121 | 0.230 |
Why?
| Molecular Sequence Annotation | 2 | 2020 | 83 | 0.230 |
Why?
| Severity of Illness Index | 4 | 2023 | 2590 | 0.230 |
Why?
| Child, Preschool | 7 | 2018 | 9164 | 0.220 |
Why?
| Patient Selection | 3 | 2013 | 655 | 0.220 |
Why?
| Feeding Behavior | 1 | 2009 | 574 | 0.220 |
Why?
| Disease Progression | 3 | 2020 | 2423 | 0.220 |
Why?
| Genotype | 3 | 2018 | 1830 | 0.220 |
Why?
| Insurance Claim Review | 2 | 2015 | 67 | 0.210 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 107 | 0.210 |
Why?
| Face | 2 | 2019 | 168 | 0.210 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 2 | 0.210 |
Why?
| Receptors, Calcitriol | 2 | 2012 | 53 | 0.210 |
Why?
| Health Maintenance Organizations | 2 | 2014 | 96 | 0.200 |
Why?
| Quality of Life | 2 | 2017 | 2390 | 0.200 |
Why?
| Eczema | 1 | 2023 | 83 | 0.200 |
Why?
| Ascorbic Acid | 1 | 2022 | 113 | 0.200 |
Why?
| Immunohistochemistry | 3 | 2019 | 1644 | 0.200 |
Why?
| Multifactorial Inheritance | 2 | 2019 | 128 | 0.200 |
Why?
| Neoplasms | 4 | 2021 | 2114 | 0.200 |
Why?
| Endorphins | 1 | 2021 | 7 | 0.200 |
Why?
| Rheumatic Diseases | 1 | 2022 | 49 | 0.200 |
Why?
| Blood Coagulation Disorders | 1 | 2004 | 196 | 0.190 |
Why?
| Immunocompromised Host | 3 | 2019 | 197 | 0.190 |
Why?
| Rituximab | 1 | 2022 | 149 | 0.190 |
Why?
| Forkhead Transcription Factors | 1 | 2022 | 170 | 0.190 |
Why?
| Electronics | 1 | 2021 | 68 | 0.190 |
Why?
| Internet | 2 | 2017 | 601 | 0.190 |
Why?
| Wnt-5a Protein | 1 | 2020 | 19 | 0.190 |
Why?
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 21 | 0.190 |
Why?
| Biomarkers | 2 | 2017 | 3474 | 0.190 |
Why?
| Venous Thrombosis | 1 | 2022 | 147 | 0.190 |
Why?
| Child | 10 | 2018 | 18537 | 0.190 |
Why?
| Causality | 1 | 2021 | 106 | 0.180 |
Why?
| Pulmonary Embolism | 1 | 2022 | 182 | 0.180 |
Why?
| Molecular Targeted Therapy | 2 | 2021 | 348 | 0.180 |
Why?
| Product Surveillance, Postmarketing | 1 | 2020 | 63 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1137 | 0.180 |
Why?
| Boston | 1 | 2020 | 75 | 0.170 |
Why?
| Parents | 2 | 2018 | 1208 | 0.170 |
Why?
| Data Curation | 1 | 2019 | 11 | 0.170 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 1725 | 0.170 |
Why?
| Xeroderma Pigmentosum | 1 | 2019 | 7 | 0.170 |
Why?
| Histocompatibility Testing | 1 | 2019 | 116 | 0.170 |
Why?
| Antirheumatic Agents | 1 | 2022 | 255 | 0.170 |
Why?
| Physicians, Primary Care | 2 | 2013 | 222 | 0.170 |
Why?
| Symbiosis | 1 | 2019 | 65 | 0.160 |
Why?
| Repressor Proteins | 1 | 2022 | 369 | 0.160 |
Why?
| Algorithms | 4 | 2016 | 1494 | 0.160 |
Why?
| Antibodies, Monoclonal | 2 | 2017 | 1264 | 0.160 |
Why?
| Torso | 1 | 2019 | 30 | 0.160 |
Why?
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.160 |
Why?
| Gene-Environment Interaction | 1 | 2020 | 185 | 0.160 |
Why?
| Quantitative Trait Loci | 1 | 2020 | 322 | 0.160 |
Why?
| Administration, Cutaneous | 1 | 2018 | 116 | 0.160 |
Why?
| Predictive Value of Tests | 3 | 2013 | 1813 | 0.160 |
Why?
| Health Care Surveys | 2 | 2017 | 540 | 0.160 |
Why?
| Survival Analysis | 3 | 2016 | 1218 | 0.160 |
Why?
| Head | 1 | 2019 | 87 | 0.160 |
Why?
| Off-Label Use | 1 | 2018 | 52 | 0.160 |
Why?
| Biopsy | 3 | 2013 | 1056 | 0.160 |
Why?
| Extremities | 1 | 2019 | 113 | 0.150 |
Why?
| Longitudinal Studies | 2 | 2018 | 2416 | 0.150 |
Why?
| Policy | 1 | 2019 | 140 | 0.150 |
Why?
| Documentation | 1 | 2019 | 169 | 0.150 |
Why?
| Evidence-Based Practice | 1 | 2019 | 191 | 0.150 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 130 | 0.150 |
Why?
| Vaccines | 1 | 2023 | 376 | 0.150 |
Why?
| Injections, Subcutaneous | 1 | 2018 | 137 | 0.150 |
Why?
| Receptor, Melanocortin, Type 1 | 1 | 2017 | 23 | 0.150 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 816 | 0.150 |
Why?
| Immunotherapy | 1 | 2021 | 481 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2019 | 153 | 0.150 |
Why?
| Random Allocation | 1 | 2018 | 337 | 0.150 |
Why?
| Ultraviolet Therapy | 1 | 2017 | 16 | 0.140 |
Why?
| Disease-Free Survival | 2 | 2016 | 621 | 0.140 |
Why?
| Family | 2 | 2011 | 597 | 0.140 |
Why?
| Merkel cell polyomavirus | 1 | 2016 | 3 | 0.140 |
Why?
| Cryosurgery | 2 | 2021 | 52 | 0.140 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2017 | 65 | 0.140 |
Why?
| Tumor Virus Infections | 1 | 2016 | 41 | 0.140 |
Why?
| Drug Utilization | 1 | 2017 | 167 | 0.140 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2016 | 23 | 0.140 |
Why?
| Genotyping Techniques | 1 | 2016 | 72 | 0.140 |
Why?
| Paraneoplastic Syndromes | 1 | 2016 | 13 | 0.140 |
Why?
| Drug Prescriptions | 1 | 2018 | 241 | 0.140 |
Why?
| Immunity | 1 | 2017 | 125 | 0.130 |
Why?
| Sunburn | 2 | 2018 | 25 | 0.130 |
Why?
| International Classification of Diseases | 2 | 2015 | 118 | 0.130 |
Why?
| Intention | 1 | 2017 | 143 | 0.130 |
Why?
| Spondylarthritis | 1 | 2016 | 36 | 0.130 |
Why?
| Genetic Variation | 1 | 2021 | 893 | 0.130 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2023 | 1193 | 0.130 |
Why?
| Spondylitis, Ankylosing | 1 | 2016 | 43 | 0.130 |
Why?
| Aspergillus | 1 | 2015 | 17 | 0.130 |
Why?
| Viral Load | 1 | 2017 | 406 | 0.130 |
Why?
| Practice Guidelines as Topic | 2 | 2021 | 1405 | 0.130 |
Why?
| Aspergillosis | 1 | 2015 | 24 | 0.130 |
Why?
| Pharmaceutical Services | 1 | 2016 | 79 | 0.130 |
Why?
| Gene Frequency | 1 | 2017 | 506 | 0.130 |
Why?
| Body Mass Index | 2 | 2021 | 1974 | 0.130 |
Why?
| Linear Models | 1 | 2018 | 777 | 0.130 |
Why?
| Voriconazole | 1 | 2015 | 24 | 0.130 |
Why?
| Cause of Death | 1 | 2017 | 368 | 0.130 |
Why?
| Surgeons | 1 | 2019 | 238 | 0.130 |
Why?
| Transcriptome | 1 | 2020 | 742 | 0.130 |
Why?
| Referral and Consultation | 1 | 2020 | 647 | 0.130 |
Why?
| Fetal Blood | 1 | 2017 | 269 | 0.130 |
Why?
| Cluster Analysis | 1 | 2016 | 466 | 0.130 |
Why?
| Patient Education as Topic | 1 | 2020 | 685 | 0.120 |
Why?
| Sex Characteristics | 1 | 2019 | 643 | 0.120 |
Why?
| Stevens-Johnson Syndrome | 1 | 2015 | 34 | 0.120 |
Why?
| Motivation | 1 | 2019 | 496 | 0.120 |
Why?
| Sebaceous Glands | 1 | 2014 | 4 | 0.120 |
Why?
| Kava | 1 | 2014 | 2 | 0.120 |
Why?
| Health Personnel | 2 | 2017 | 579 | 0.120 |
Why?
| Drug Eruptions | 1 | 2014 | 26 | 0.120 |
Why?
| Plant Preparations | 1 | 2014 | 23 | 0.120 |
Why?
| Transcription, Genetic | 1 | 2020 | 1317 | 0.120 |
Why?
| Multivariate Analysis | 3 | 2016 | 1443 | 0.120 |
Why?
| Infant | 4 | 2014 | 7992 | 0.120 |
Why?
| Stomach Neoplasms | 1 | 2015 | 66 | 0.120 |
Why?
| Phytotherapy | 1 | 2014 | 66 | 0.120 |
Why?
| Animals | 7 | 2021 | 32158 | 0.120 |
Why?
| Gastrectomy | 1 | 2015 | 83 | 0.120 |
Why?
| Infant, Newborn | 3 | 2014 | 5084 | 0.120 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 688 | 0.110 |
Why?
| Exanthema | 1 | 2014 | 77 | 0.110 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2014 | 98 | 0.110 |
Why?
| Signal Transduction | 2 | 2019 | 4527 | 0.110 |
Why?
| Mutation | 3 | 2019 | 3371 | 0.110 |
Why?
| Clinical Coding | 1 | 2013 | 20 | 0.110 |
Why?
| Biomarkers, Tumor | 1 | 2019 | 1045 | 0.110 |
Why?
| Lung Transplantation | 1 | 2015 | 246 | 0.110 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1143 | 0.110 |
Why?
| Systematized Nomenclature of Medicine | 1 | 2013 | 10 | 0.110 |
Why?
| Arthritis, Juvenile | 1 | 2013 | 42 | 0.110 |
Why?
| Lip Neoplasms | 1 | 2012 | 1 | 0.110 |
Why?
| Mortality | 1 | 2015 | 290 | 0.110 |
Why?
| Sunscreening Agents | 1 | 2012 | 17 | 0.110 |
Why?
| Hydrochlorothiazide | 1 | 2012 | 8 | 0.110 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2012 | 448 | 0.110 |
Why?
| Nifedipine | 1 | 2012 | 29 | 0.110 |
Why?
| Genetic Testing | 2 | 2019 | 383 | 0.110 |
Why?
| Calcium, Dietary | 1 | 2012 | 55 | 0.110 |
Why?
| Methotrexate | 1 | 2013 | 228 | 0.100 |
Why?
| Health Services Accessibility | 1 | 2018 | 771 | 0.100 |
Why?
| Professional Competence | 1 | 2012 | 86 | 0.100 |
Why?
| Computer-Assisted Instruction | 1 | 2012 | 64 | 0.100 |
Why?
| Graft Rejection | 1 | 2015 | 533 | 0.100 |
Why?
| Fees and Charges | 1 | 2011 | 9 | 0.100 |
Why?
| Private Practice | 1 | 2011 | 20 | 0.100 |
Why?
| Diagnosis, Differential | 3 | 2007 | 1359 | 0.100 |
Why?
| Marital Status | 1 | 2011 | 41 | 0.100 |
Why?
| Electrosurgery | 1 | 2012 | 43 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2023 | 1872 | 0.100 |
Why?
| Nutrition Surveys | 1 | 2012 | 225 | 0.100 |
Why?
| Hedgehog Proteins | 1 | 2012 | 172 | 0.100 |
Why?
| Homeodomain Proteins | 1 | 2015 | 465 | 0.100 |
Why?
| Food | 1 | 2012 | 160 | 0.090 |
Why?
| Postoperative Hemorrhage | 1 | 2011 | 78 | 0.090 |
Why?
| Curriculum | 1 | 2017 | 856 | 0.090 |
Why?
| Physicians | 1 | 2019 | 777 | 0.090 |
Why?
| Basal Cell Nevus Syndrome | 1 | 2010 | 5 | 0.090 |
Why?
| Immune Tolerance | 1 | 2012 | 331 | 0.090 |
Why?
| Program Development | 1 | 2012 | 350 | 0.090 |
Why?
| Aspirin | 1 | 2013 | 326 | 0.090 |
Why?
| DNA Damage | 1 | 2012 | 356 | 0.090 |
Why?
| Faculty, Medical | 1 | 2012 | 234 | 0.090 |
Why?
| Neoplasms, Basal Cell | 1 | 2009 | 3 | 0.090 |
Why?
| Family Relations | 1 | 2010 | 87 | 0.090 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 4447 | 0.090 |
Why?
| Education, Medical | 1 | 2012 | 225 | 0.090 |
Why?
| Life Style | 1 | 2012 | 428 | 0.080 |
Why?
| Behavior Therapy | 1 | 2011 | 226 | 0.080 |
Why?
| Genetic Counseling | 1 | 2009 | 67 | 0.080 |
Why?
| Lung Neoplasms | 1 | 2022 | 2206 | 0.080 |
Why?
| Phylogeny | 2 | 2015 | 806 | 0.080 |
Why?
| Eggs | 1 | 2009 | 30 | 0.080 |
Why?
| Fishes | 1 | 2009 | 81 | 0.080 |
Why?
| Energy Metabolism | 1 | 2013 | 713 | 0.080 |
Why?
| Northwestern United States | 1 | 2008 | 54 | 0.080 |
Why?
| Adenocarcinoma | 1 | 2015 | 797 | 0.080 |
Why?
| Time Factors | 3 | 2017 | 6182 | 0.080 |
Why?
| Milk | 1 | 2009 | 124 | 0.080 |
Why?
| Pemphigus | 1 | 2007 | 8 | 0.080 |
Why?
| Health Behavior | 2 | 2017 | 704 | 0.080 |
Why?
| Cervix Uteri | 1 | 2007 | 44 | 0.070 |
Why?
| Prostatic Neoplasms | 1 | 2015 | 927 | 0.070 |
Why?
| Postoperative Complications | 2 | 2015 | 2164 | 0.070 |
Why?
| Arthritis, Rheumatoid | 1 | 2015 | 1003 | 0.070 |
Why?
| Risk Reduction Behavior | 1 | 2009 | 196 | 0.070 |
Why?
| Head-Down Tilt | 1 | 2007 | 5 | 0.070 |
Why?
| Torsion Abnormality | 1 | 2007 | 17 | 0.070 |
Why?
| Psychological Theory | 1 | 2007 | 96 | 0.070 |
Why?
| Disclosure | 1 | 2007 | 102 | 0.070 |
Why?
| Clinical Competence | 1 | 2013 | 924 | 0.070 |
Why?
| Sweat Gland Diseases | 1 | 2006 | 1 | 0.070 |
Why?
| Eccrine Glands | 1 | 2006 | 2 | 0.070 |
Why?
| Eosinophil-Derived Neurotoxin | 1 | 2006 | 3 | 0.070 |
Why?
| Mupirocin | 1 | 2006 | 7 | 0.070 |
Why?
| Eosinophil Major Basic Protein | 1 | 2006 | 6 | 0.070 |
Why?
| Hamartoma | 1 | 2006 | 21 | 0.070 |
Why?
| Arteriovenous Malformations | 1 | 2006 | 24 | 0.070 |
Why?
| Environmental Exposure | 1 | 2009 | 380 | 0.070 |
Why?
| Bandages | 1 | 2006 | 32 | 0.070 |
Why?
| Primary Health Care | 2 | 2017 | 1520 | 0.070 |
Why?
| Acetaminophen | 1 | 2008 | 237 | 0.060 |
Why?
| Anti-Bacterial Agents | 2 | 2023 | 1486 | 0.060 |
Why?
| Sodium Chloride | 1 | 2006 | 136 | 0.060 |
Why?
| Communication | 1 | 2010 | 749 | 0.060 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 59 | 0.060 |
Why?
| Vaccination | 2 | 2023 | 1209 | 0.060 |
Why?
| Necrosis | 1 | 2005 | 211 | 0.060 |
Why?
| Patient-Centered Care | 1 | 2009 | 477 | 0.060 |
Why?
| Societies, Medical | 2 | 2018 | 685 | 0.060 |
Why?
| Cyclooxygenase 2 | 1 | 2004 | 165 | 0.060 |
Why?
| Isoenzymes | 1 | 2004 | 287 | 0.060 |
Why?
| Skin Transplantation | 1 | 2004 | 58 | 0.060 |
Why?
| New York | 1 | 2023 | 110 | 0.060 |
Why?
| Socioeconomic Factors | 2 | 2021 | 1088 | 0.050 |
Why?
| Public Health | 1 | 2007 | 438 | 0.050 |
Why?
| Mucous Membrane | 1 | 2023 | 108 | 0.050 |
Why?
| Hand | 1 | 2004 | 135 | 0.050 |
Why?
| Infant, Premature | 1 | 2006 | 477 | 0.050 |
Why?
| Diclofenac | 1 | 2021 | 14 | 0.050 |
Why?
| Hospitalization | 2 | 2023 | 1764 | 0.050 |
Why?
| Delphi Technique | 1 | 2021 | 164 | 0.050 |
Why?
| Combined Modality Therapy | 1 | 2023 | 1127 | 0.050 |
Why?
| B7-H1 Antigen | 1 | 2022 | 138 | 0.050 |
Why?
| Adrenal Cortex Hormones | 1 | 2004 | 510 | 0.040 |
Why?
| Ligands | 1 | 2022 | 570 | 0.040 |
Why?
| Ipilimumab | 1 | 2019 | 28 | 0.040 |
Why?
| Oncogenes | 1 | 2019 | 104 | 0.040 |
Why?
| Membrane Proteins | 1 | 2004 | 1033 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 177 | 0.040 |
Why?
| Keratoacanthoma | 1 | 2017 | 2 | 0.040 |
Why?
| Photosensitivity Disorders | 1 | 2017 | 7 | 0.040 |
Why?
| PUVA Therapy | 1 | 1997 | 5 | 0.040 |
Why?
| Retinoids | 1 | 2017 | 31 | 0.040 |
Why?
| Capecitabine | 1 | 2017 | 46 | 0.040 |
Why?
| Risk Adjustment | 1 | 2018 | 75 | 0.040 |
Why?
| Reimbursement Mechanisms | 1 | 2018 | 78 | 0.040 |
Why?
| Vitamin B Complex | 1 | 2017 | 37 | 0.040 |
Why?
| Databases, Genetic | 1 | 2018 | 211 | 0.040 |
Why?
| Observational Studies as Topic | 1 | 2018 | 89 | 0.040 |
Why?
| Niacinamide | 1 | 2017 | 65 | 0.040 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2017 | 83 | 0.040 |
Why?
| Primary Prevention | 1 | 2018 | 170 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 2017 | 182 | 0.040 |
Why?
| Pregnancy Trimester, Second | 1 | 2017 | 66 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2001 | 944 | 0.030 |
Why?
| Rheumatologists | 1 | 2016 | 12 | 0.030 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 312 | 0.030 |
Why?
| Computers | 1 | 2016 | 60 | 0.030 |
Why?
| Drugs, Generic | 1 | 2016 | 18 | 0.030 |
Why?
| Pregnancy Trimester, First | 1 | 2017 | 129 | 0.030 |
Why?
| Sampling Studies | 1 | 2016 | 95 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 183 | 0.030 |
Why?
| RNA, Viral | 1 | 2019 | 564 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1360 | 0.030 |
Why?
| Medical Records Systems, Computerized | 1 | 2016 | 90 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 319 | 0.030 |
Why?
| Mice | 3 | 2021 | 15085 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 526 | 0.030 |
Why?
| Research | 1 | 2018 | 398 | 0.030 |
Why?
| Pandemics | 1 | 2023 | 1337 | 0.030 |
Why?
| Pharmacoepidemiology | 1 | 2015 | 20 | 0.030 |
Why?
| Health Expenditures | 1 | 2016 | 173 | 0.030 |
Why?
| Erythema | 1 | 2014 | 25 | 0.030 |
Why?
| Disease Management | 1 | 2018 | 563 | 0.030 |
Why?
| Gene Expression | 1 | 2020 | 1442 | 0.030 |
Why?
| Antifungal Agents | 1 | 2015 | 134 | 0.030 |
Why?
| Papillomavirus Vaccines | 1 | 2017 | 222 | 0.030 |
Why?
| Prenatal Care | 1 | 2017 | 257 | 0.030 |
Why?
| Germ-Line Mutation | 1 | 2015 | 134 | 0.030 |
Why?
| Phototherapy | 1 | 2013 | 24 | 0.030 |
Why?
| Infliximab | 1 | 2013 | 94 | 0.030 |
Why?
| Computer User Training | 1 | 2012 | 6 | 0.030 |
Why?
| Graft Survival | 1 | 2015 | 481 | 0.030 |
Why?
| Medicaid | 1 | 2016 | 411 | 0.030 |
Why?
| Feasibility Studies | 1 | 2015 | 750 | 0.030 |
Why?
| Codon | 1 | 2012 | 86 | 0.020 |
Why?
| Washington | 1 | 2012 | 136 | 0.020 |
Why?
| Ibuprofen | 1 | 2012 | 73 | 0.020 |
Why?
| Medicare | 1 | 2016 | 666 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2018 | 2807 | 0.020 |
Why?
| Postmenopause | 1 | 2013 | 301 | 0.020 |
Why?
| Regression Analysis | 1 | 2012 | 960 | 0.020 |
Why?
| Coccidioidomycosis | 1 | 1970 | 7 | 0.020 |
Why?
| Histoplasmosis | 1 | 1970 | 16 | 0.020 |
Why?
| Early Diagnosis | 1 | 2011 | 220 | 0.020 |
Why?
| Lipids | 1 | 2013 | 589 | 0.020 |
Why?
| Michigan | 1 | 2009 | 96 | 0.020 |
Why?
| Skin Tests | 1 | 1970 | 137 | 0.020 |
Why?
| Family Characteristics | 1 | 2010 | 154 | 0.020 |
Why?
| Health Surveys | 1 | 1970 | 447 | 0.020 |
Why?
| Papanicolaou Test | 1 | 2007 | 39 | 0.020 |
Why?
| Vaginal Smears | 1 | 2007 | 48 | 0.020 |
Why?
| Blood Pressure | 1 | 2013 | 1537 | 0.020 |
Why?
| Psychology | 1 | 2007 | 83 | 0.020 |
Why?
| Precancerous Conditions | 1 | 2007 | 156 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2011 | 1217 | 0.020 |
Why?
| Colorectal Neoplasms | 1 | 2012 | 617 | 0.020 |
Why?
| Pregnancy | 1 | 2017 | 5555 | 0.020 |
Why?
| Blood Glucose | 1 | 2013 | 1826 | 0.020 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 29 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1997 | 1001 | 0.010 |
Why?
| Histoplasmin | 1 | 1970 | 1 | 0.010 |
Why?
| Mass Chest X-Ray | 1 | 1970 | 4 | 0.010 |
Why?
| Coccidioides | 1 | 1970 | 4 | 0.010 |
Why?
| Histoplasma | 1 | 1970 | 14 | 0.010 |
Why?
| Iran | 1 | 1970 | 35 | 0.010 |
Why?
| Blood Cell Count | 1 | 1970 | 52 | 0.010 |
Why?
| Occupations | 1 | 1970 | 36 | 0.010 |
Why?
| Tuberculin Test | 1 | 1970 | 32 | 0.010 |
Why?
| Climate | 1 | 1970 | 85 | 0.010 |
Why?
| Antigens | 1 | 1970 | 322 | 0.000 |
Why?
| Sputum | 1 | 1970 | 291 | 0.000 |
Why?
| Soil Microbiology | 1 | 1970 | 177 | 0.000 |
Why?
| Rural Population | 1 | 1970 | 448 | 0.000 |
Why?
|
|
Asgari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|